ABSTRACT
The sequences were randomized based on the Williams design for a cross-over study to reduce the "carryover" effects from drug-todrug even with sufficient washout periods.
Digital 12-lead electrocardiograms were recorded at nine time points over 24 hours in each period. QT intervals were corrected for heart rate using a study-specific correction factor (QTcX) and Fridericia's formula. Results:
For dapagliflozin, the upper bound of the one-sided 95% confidence interval (CI) for time-matched, placebo-subtracted, baseline adjusted QTc intervals (∆∆QTc) was <10 ms. Dapagliflozin is a first-in-class oral, oncedaily, potent, and highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor being developed for the treatment of T2DM. 3, 4 Treatment with dapagliflozin promotes urinary glucose excretion by preventing up to 50% of the filtered glucose from being reabsorbed. 5, 6 Thus, by inhibiting renal glucose reabsorption, SGLT2 inhibition provides a mechanism for improving glycemic control in patients with T2DM that is independent of insulin secretion or insulin action. were obtained throughout the study and at a follow-up examination 5-7 days after the last treatment period. All adverse events (AEs) were evaluated by the investigator and characterized with respect to intensity, duration, relationship to study drug, and outcome.
Pharmacodynamic Measurements

Recording of Digital Electrocardiogram
Twelve-lead continuous digital ECG (dECG)
recordings were obtained using a Schiller 
Determination of Digital Electrocardiogram Parameters
The following dECG variables were reported: RR interval, PR interval, QRS interval, QT tang interval, and QT interval corrected for heart rate using a and ≤9.5%, and ±7.3%. For both dapagliflozin and BMS-801576, the assay range representing the lower and upper limits of quantification in plasma was 1.0-500 ng/mL.
Statistical Analysis
The If the slope was significant, the predicted ΔΔQTcX and its corresponding upper 90%
two-sided CI bound were to be computed at the C max of the therapeutic dose of dapagliflozin.
RESULTS
A total of 50 healthy men were randomized and received study drug. Enrolled subjects ranged in age from 19 to 44 years (mean, 32 years) and in BMI from 20 to 28 kg/m 2 (mean 25 kg/m 2 ).
They were classified by race as white, 14 (28%); black, 34 (68%); Asian, 1 (2%), and American
Indian or Alaska Native, 1 (2%). Thirteen subjects discontinued from the study. Of those 13 subjects, six were unwilling to continue the protocol, and three were removed for severe noncompliance with the protocol. One subject was withdrawn for AEs (pharyngeal pain, myalgias, and headache). Two subjects were withdrawn at the request of the investigator, one for pruritus and urticaria, and the other because he developed a resting heart rate <50 beats/min before dosing in one period.
The final subject withdrawn from the study developed hypertension; he later admitted to stopping hypertension medications before randomization, and thus was ineligible for inclusion in the study.
QTc Interval
The value of the study-specific correction factor Table 1) .
Similar findings were observed using QTcF.
The maximum placebo-subtracted, baselineadjusted mean effect for QTcF was 2.8 ms (90% CI, 0.6 to 5.1) and 1.6 ms (90% CI, −0.7 to 3.9) for the 20 mg and 150 mg dapagliflozin doses, respectively ( Table 1 ). The findings for QTcB were consistent with those for QTcF. CI=confidence interval; QTcF=QT interval corrected using Fridericia's formula; QTcX=QT interval corrected for heart rate using a study-specific factor. 
Effect on RR, QRS, and PR Intervals
There was little effect of dapagliflozin on heart rate. The mean change from baseline in the *Data for tmax are median (range); all others are geometric mean (coefficient of variation, %). AUC=area under the plasma concentration-time curve from 0 to infinity; C max =maximum plasma drug concentration; t 1/2 =half-life; t max =time to reach C max .
-127.8 ms for moxifloxacin 400 mg, and 20.4 to -128.1 ms for placebo. Results were similar for QRS and PR intervals regardless of treatment (Table 2) .
Pharmacokinetics
Pharmacokinetic parameters of dapagliflozin and BMS-801576 are presented in Table 3 .
Dapagliflozin was rapidly absorbed after oral administration, with a median time to C max of 1 hour for both the 20 mg and 150 mg doses.
The geometric C max and AUC values appeared to increase in a dose-proportional manner.
The geometric mean t 1/2 was 14. In addition to the standard analysis of a TQT study, this study also incorporated concentration-QT modeling. 15 The QTc versus concentration plot for dapagliflozin was essentially flat, with a slope that was not significantly different from zero. As ΔΔQTcX was independent of dapagliflozin plasma concentration, no further concentration/ QT modeling was explored. However, the concentration-QT modeling was consistent with the earlier phase 1 studies, which incorporated greater doses of dapagliflozin than the supratherapeutic dose used in this study. As some have noted, 16 if the concentration-QT modeling in early clinical studies suggests that the TQT will be negative, the standard therapeutic dose can be omitted, allowing one arm of the study to be dropped. Although the anticipated maximum therapeutic dose was included, it could have been omitted without altering the conclusions on cardiac repolarization by dapagliflozin. for the QTc effect of moxifloxacin is known, and the peak effect occurs around the time of C max (ie, no hysteresis). 18 Because moxifloxacin pharmacokinetic samples were not analyzed in this study, an average approach for C max was chosen because the mean t max was unknown. It was prospectively decided to average the ΔΔQTcX for moxifloxacin over the 1-4-hour time points that encompass the tmax range for moxifloxacin.
The ΔΔQTcX for the 1-4-hour average was 7.7 ms, with a lower bound of the 90% CI of 6.2 ms.
The maximum baseline-adjusted, placebosubtracted QTcX for moxifloxacin was 9.7 ms, and the shape of the ΔΔQTcX versus time curve for moxifloxacin was consistent with previously published data. 18 Therefore, assay sensitivity was confirmed in a rigorous way, validating the interpretability of the results for dapagliflozin.
Although the discontinuation rate of subjects in this study was greater than expected, it did not impact the results. A four-period crossover trial with a relatively long washout contributed to the dropout rate, as half of the discontinued subjects were dropouts and three additional subjects failed to comply with the protocol requirements. Both the dapagliflozin pharmacokinetic parameters and safety profile are consistent with previous results in healthy volunteers. 5 The supratherapeutic dose of 
